Similarly, analyses stratified by age, gender, history of cardiovascular disease, hypertension, type 2 diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular disease, dementia, or number of comorbidities showed no clinically significant differences though meloxicam was marginally statistically significant at 30 and 60 days.
← all excerpts
Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19.
1
—
—